Why You Should Attend

• Become familiarized
  with pharma­codynamic drug interactions
• Get comprehensively informed
  about in vitro and in vivo aspects of the ICH M12 drug interaction guide­line from regulatory and industry perspectives
• Build up knowledge
  on biomarkers for detecting clinical DDIs
• Update yourself
  on the role of liquid biopsy in assessing the induction / suppression of enzymes and transporters 
• See what Is behind the smokescreen:
  Review of methodological aspects of smoking interaction studies over the last three decades and implications for future clinical trials 
• Reflect and compare methodo­logical standards
  of food effect studies vs smoking interaction studies
• Hear about the latest update on FDA scientific efforts
  in the investigation of excipient drug interactions
• Be informed about
  the DDI potential of major pharmaceutical excipients on transporters and enzymes
• Get an overview of 2022 NDA Reviews:
  Understand the risk of metabolism- and transporter-­based DDIs with novel drugs approved by the US FDA
• Hear about the latest update
  on the PBPK model repository

… and most importantly meet, discuss and network
with a unique community of scientific and regulatory experts from pharmaceutical and contract research-industries, international regulatory bodies, non-government organizations and academia.